Spondyloarthropathies News

Secukinumab may be an effective treatment for patients with psoriatic arthritis, according to findings presented at the American College of Rheumatology Annual Meeting.

One of the hottest topics at the American College of Rheumatology Annual Meeting was new data on therapeutic targets in the treatment of spondyloarthropathies, with many “interesting papers” , according to Beth L. Jonas, MD, FACR, professor of medicine and interim chief of the division of rheumatology, allergy and immunology in the Thurston Arthritis Research Center at UNC.

The use of opioids among patients with ankylosing spondylitis is more likely to be associated with subjective measures, such as depression, than objective measures like C-reactive protein levels and erythrocyte sedimentation rate, according to findings published in the Journal of Rheumatology.

An MRI screening of the sacroiliac joints showed that a large proportion of healthy, active individuals who lack any back-pain symptoms nonetheless have bone marrow edema lesions, according to data published in Rheumatology. However, such lesions did not grow significantly after 6 weeks of intensive physical training.

Multinational biopharmaceutical company UBC has announced that its phase 2b BE AGILE study has established a dose response, as well as statistically significant efficacy, for bimekizumab as a treatment for adults with ankylosing spondylitis, according to a press release.

In this guest commentary, Vivian P. Bykerk, BSc, MD, FRCPC, discusses the relationship between obesity and disease outcomes in axial spondyloarthropathy following a presentation on the topic at the American College of Rheumatology Annual Meeting. Bykerk is associate attending rheumatologist and director of the Inflammatory Arthritis Center of Excellence at the Hospital for Special Surgery and associate professor of medicine at Weill Cornell Medical College.

SAN DIEGO – High BMI may be an independent predictor of worse disease outcomes and increased comorbidity among patients with axial spondyloarthropathy, according to findings presented at the American College of Rheumatology Annual Meeting.

ORLANDO, Fla. — Templating, bone grafting and using a rim-fitting porous cup are effective for addressing primary or secondary acetabular protrusio, a rare problem that can occur in patients with rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteomalacia or Paget’s disease, as well as in post-traumatic situations.

The FDA has approved the third biosimilar to infliximab, infliximab-qbtx, for all eligible indications of the biologic product, according to a company press release.

SAN DIEGO – Patients with spondyloarthropathies appear to be at higher risk for deep vein thrombosis and pulmonary embolism, according to results presented at the American College of Rheumatology Annual Meeting.